^
BIOMARKER:

NTRK3 fusion

i
Other names: NTRK3, TRKC, Neurotrophic tyrosine kinase, receptor, type 3
Entrez ID:
NTRK3 fusion
Sarcoma
larotrectinib
Sensitive: A1 - Approval
NTRK3 fusion
Solid Tumor
entrectinib
Sensitive: A1 - Approval
NTRK3 fusion
Solid Tumor
larotrectinib
Sensitive: A1 - Approval
NTRK3 fusion
Small Intestinal Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Soft Tissue Sarcoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Pancreatic Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Breast Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
GIST
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Sarcoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Peritoneal Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Peritoneal Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Fallopian Tube Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Fallopian Tube Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
NSCLC
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Pancreatic Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Endometrial Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
GIST
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Small Intestinal Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Pancreatic Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Pancreatic Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Papillary Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Soft Tissue Sarcoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Gastroesophageal Junction Adenocarcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Esophageal Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Gastroesophageal Junction Adenocarcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Esophageal Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Cervical Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Cervical Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
NSCLC
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Biliary Tract Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Biliary Tract Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Breast Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Melanoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
CRC
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
HCC
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
HCC
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Ovarian Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Ovarian Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
CRC
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Anaplastic Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Anaplastic Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Salivary Gland Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Endometrial Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Salivary Gland Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Gastric Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Gastric Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Melanoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Thyroid Gland Hurthle Cell Carcinoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Cutaneous Melanoma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Cutaneous Melanoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Glioma
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Rectal Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Rectal Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Glioma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Vulvar Cancer
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Vulvar Cancer
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
GBM
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
GBM
larotrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Solid Tumor
TPX-0005
Sensitive: B - Late Trials
NTRK3 fusion
Solid Tumor
Trk inhibitor
Sensitive: B - Late Trials
NTRK3 fusion
Neurofibrosarcoma
entrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
Spindle Cell Sarcoma
entrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
Gastrointestinal Cancer
larotrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
Gastrointestinal Cancer
entrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
Small Cell Lung Cancer
larotrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
Fibrosarcoma
larotrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
Cholangiocarcinoma
larotrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
Osteosarcoma
larotrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
Thyroid Gland Carcinoma
larotrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
Cholangiocarcinoma
entrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
Colon Cancer
larotrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
Esophageal Squamous Cell Carcinoma
larotrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
Lung Cancer
larotrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
CNS Tumor
larotrectinib
Sensitive: C1 - Off-label
NTRK3 fusion
CRC
Immunotherapy
Sensitive: C3 – Early Trials
NTRK3 fusion
Glioma
entrectinib + abemaciclib
Sensitive: D – Preclinical
NTRK3 fusion
Glioma
trametinib + entrectinib
Sensitive: D – Preclinical
NTRK3 fusion
Solid Tumor
SIM1803-1A
Sensitive: D – Preclinical